Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood

Journal of Cancer Survivorship

Volumn 6, Issue 1, 2012, Pages 95-101

  Vandecruys, Els ^a   Mondelaers, Veerle ^a   de Wolf, Daniel ^a   Benoit, Yves ^a   Suys, Bert ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

ALL; Anthracycline related cardiotoxicity; Cardiotoxicity after cancer therapy; Late effects

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC ANTIBIOTIC;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; CHILD; DISEASE FREE SURVIVAL; DOSE RESPONSE; ECHOGRAPHY; FEMALE; HEART DISEASE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HUMAN; INFANT; MALE; MIDDLE AGED; PATHOLOGY; PRESCHOOL CHILD; SEX DIFFERENCE; SURVIVOR; TIME;

ADOLESCENT; ADULT; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART DISEASES; HUMANS; INFANT; MALE; MIDDLE AGED; MYOCARDIUM; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SEX FACTORS; SURVIVORS; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT; YOUNG ADULT;

EID: 84857141781     PISSN: 19322259     EISSN: 19322267     Source Type: Journal    
DOI: 10.1007/s11764-011-0186-6     Document Type: Article

References (27)

1. Goorin AM, Chauvenet AR, Perez-Atayde AR, et al. Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer. J Pediatr. 1990; 116: 144-7.
2. Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991; 324: 808-15.
3. Steinherz LJ, Steinherz P, Tan CTC, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991; 266: 1672-7.
4. Sorensen K, Levitt G, Sebag-Montefiore D, et al. Anthracycline dose in childhood acute lymphoblastic leukemia: Issues of early survival versus late cardiotoxicity. J Clin Oncol. 1997; 15: 61-8.
5. Nysom K, Holm K, Lipsitz SR, et al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol. 1998; 16: 545-50.
6. Rammeloo LAJ, Postma A, Soboka-Plojhar MA. Low-dose daunorubicin in induction treatment of childhood acute lymphoblastic leukaemia: no long-term cardiac damage in a randomised study of the Dutch childhood leukaemia study group. Med Ped Oncol. 2000; 35: 136-9.
7. De Wolf D, Suys B, Maurus R, et al. Dobutamine stress echocardiography in the evaluation of late anthracycline cardiotoxicity in childhood cancer survivors. Pediatr Res. 1996; 39: 504-12.
8. Dorup I, Levitt G, Sullivan I, Sorensen K. Prospective longitudinal assessment of late anthracycline cardiotoxicity after childhood cancer: the role of diastolic function. Heart. 2004; 90: 1214-16.
9. Suys BE, Katier N, Rooman RP, et al. Female children and adolescents with type 1 diabetes have more pronounced early echocardiographic signs of diabetic cardiomyo-pathy. Diabetes Care. 2004; 27: 1947-53.
10. Kapusta L, Thijssen JM, Groot-Loonen J, et al. Tissue Doppler Imaging in detection of myocardial dysfunction in survivors of childhood cancer treated with anthracyclines. Ultrasound Med Biol. 2000; 26(7): 1099-108.
11. Vilmer E, Suciu S, Ferster A, et al. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC Report. Children Leukemia Cooperative Group. Leukemia. 2000; 14(12): 2257-66.
12. Rowland DG, Gutgesell HP. Use of mean arterial pressure for noninvasive determination of left ventricular end-systolic wall stress in infants and children. Am J Cardiol. 1994; 4: 98-9.
13. Devereux RB, Lutas EM, Casale PN, et al. Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol. 1984; 4: 1222-30.
14. Tei C. New noninvasive index for combined systolic and diastolic ventricular function. J Cardiol. 1995; 26: 135-6.
15. Sorensen K, Levitt GA, Bull C, et al. Late anthracycline cardiotoxicity after childhood cancer. A prospective longitudinal study. Cancer. 2003; 97: 1991-8.
16. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005; 23: 2629-36.
17. Elbl L, Hrstkova H, Chaloupka V. The late consequences of anthracycline treatment on left ventricular function after treatment of childhood cancer. Eur J Pediatr. 2003; 162(10): 690-6.
18. Stapleton GE, Stapleton LC, Martinez A, et al. Evaluation of longitudinal ventricular function with tissue Doppler echocardiography in children treated with anthracyclines. J Am Soc Echocardiogr. 2007; 20: 492-7.
19. Rathe M, Carlsen NLT, Oxhøj H. Late cardiac effects of anthracycline containing therapy for childhood lymphoblastic leukemia. Pediatr Blood Cancer. 2007; 48: 663-7.
20. Ganame J, Cluas P, Uyttebroeck A, et al. Myocardial dysfunction late after low-dose Anthracycline treatment in asymptomatic pediatric patients. J Am Soc Echocardiogr. 2007; 20: 1351-8.
21. Eidem BW, Sapp BG, Suarez CR, et al. Usefulness of the Myocardial Performance Index for early detection of anthracycline-induced cardiotoxicity in children. Am J Cardiol. 2001; 87: 1120-2.
22. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995; 332: 1738-43.
23. Pein F, Sakiroglu O, Dahan M, et al. Cardiac abnormalities 15 years and more after Adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy. Br J Cancer. 2004; 91: 37-44.
24. van Dalen EC, van der Pal HJ, Kok WE, et al. Clinical heart failure in a cohort af children treated with anthracyclines: a long-term follow-up study. Eur J Cancer. 2006; 42: 3191-8.
25. Wouters KA, Kremer LCM, Miller TL, et al. Protecting against anthracycline-induced Myocardial damage: a review of the most promising strategies. Br J Haematol. 2005; 131: 561-78.
26. Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart. 2008; 94: 525-33.
27. Shankar SM, Marina N, Hudson MM, et al. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the carciovascular disease task force of the Children's Oncology Group. Pediatrics. 2008; 121: e387-96.